CHART-VISION: CHART Study of Coronary CT Angiography in Coronary Artery Disease

Sponsor
Shanghai Zhongshan Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT05380622
Collaborator
(none)
5,000
1
192
26

Study Details

Study Description

Brief Summary

In a cohort of patients referred to coronary computed tomography angiography (CCTA), the investigators aim:

  1. To describe the natural history of the coronary atherosclerotic plaque development and progression or regression, as well as the plaque characterization and phenotypes over time by CCTA among deferred coronary lesions

  2. To explore the precursors of plaques leading to acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) in deferred coronary lesions

  3. To investigate prognostic implication of qualitative and quantitative plaque analysis of stenosis and plaque features, disease patterns, hemodynamic parameters, and fat metrics on CCTA along with physiologic assessment

  4. To investigate the effects of different treatment strategies according to stenosis and plaque features, fat metrics on CCTA along with physiologic assessments.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Coronary CT angiography

Detailed Description

Invasive physiologic indices such as fractional flow reserve (FFR) are used to define ischemia-causing stenosis and guide percutaneous coronary intervention (PCI) in the clinical practice. FFR-guided PCI has been proven to improve clinical outcomes, however, a substantial proportion of patients continue to experience clinical events. The ISCHEMIA trial showed that invasive therapy did not improve prognosis in patients with moderate to severe ischemia compared to optimal medical therapy. Besides, a recent study implied that even in vessels with FFR>0.80, those have lesions with high-risk plaque characteristics (HRPC) demonstrated worse clinical outcomes. This might be not unexpected since previous evidence from postmortem studies demonstrated that unstable atherosclerotic plaques are prone to rupture and trigger adverse cardiovascular events.

In recent years, advances in imaging analysis made it possible to conduct novel measurements such as pericoronary inflammation or epicardial fat metrics and lesion-specific or vessel-specific hemodynamic parameters derived from CCTA (such as fractional flow reserve by CCTA [CT-FFR]) as well as the coronary disease patterns defined by physiologic distribution (predominant focal versus diffuse disease defined by CCTA derived pullback pressure gradient index) and local severity (presence versus absence of major gradient defined by CCTA-derived FFR gradient per unit length [dCT-FFR/ds]) of coronary atherosclerosis.

However, the relationship of these parameters and the combination of these indices on clinical outcomes has not been fully understood. Furthermore, though it has been known that high-risk plaques are related with worse outcomes even no significant blood flow impairment induced, best treatment strategy for these lesions remains unclear.

In this regard, the aims of this study are multiple, all the treatment strategies are at the discretion of the physicians in charge. For patients without further invasive angiography performed after CCTA or deferred for revascularization after invasive angiography with/without physiology or imaging assessments, the investigators will investigate coronary atherosclerotic plaque development and progression or regression, as well as the plaque characterization and phenotypes over time by CCTA, and to explore the precursors of plaques leading to acute coronary syndrome (ACS) or chronic coronary syndrome (CCS); for those with received revascularization, the investigators will investigate the prognostic value of CCTA based comprehensive analysis of coronary in combination with physiologic assessment. In all patients, the effects of different treatment strategies according to stenosis and plaque features, fat metrics as well as physiologic assessments will be investigated.

CHART is a study group called Chinese Non-invasive Cardiovascular Imaging and Physiology Study Group, the current study will be conducted by CHART and by invitation in multiple Chinese centers.

Study Design

Study Type:
Observational
Anticipated Enrollment :
5000 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
CHART Study of Coronary CT Angiography to Predict Imaging and Cardiovascular Outcomes in Patients With Coronary Artery Disease
Actual Study Start Date :
Jan 1, 2015
Anticipated Primary Completion Date :
Dec 31, 2025
Anticipated Study Completion Date :
Dec 31, 2030

Arms and Interventions

Arm Intervention/Treatment
Without ICA or deferral of PCI after ICA group

Patients didn't undergo invasive coronary angiography (ICA) or with a vessel determined to defer revascularization.

Diagnostic Test: Coronary CT angiography
Coronary CT angiography (CCTA) will be performed according to standard protocol and measurement of fractional flow reserve (FFR) or other physiological indices will be at the at the discretion of the physicians in charge. Stenosis and plaque features, disease patterns, hemodynamic parameters, and fat metrics on CCTA will be analyzed blindly in the core lab.

PCI group

Patients with a vessel that undergo percutaneous coronary intervention (PCI)

Diagnostic Test: Coronary CT angiography
Coronary CT angiography (CCTA) will be performed according to standard protocol and measurement of fractional flow reserve (FFR) or other physiological indices will be at the at the discretion of the physicians in charge. Stenosis and plaque features, disease patterns, hemodynamic parameters, and fat metrics on CCTA will be analyzed blindly in the core lab.

Outcome Measures

Primary Outcome Measures

  1. Frequency of occurrence of high-risk plaques [30 days]

    Frequency (%) of occurrence of high-risk plaque morphologic features (Housfield Unit[HU]<30, Remodelling Index > 1.1, napkin-ring sign, spotty calcium, minimal lumen area[MLA]<4mm2 & plaque burden[PB]≥70%), physiologic diffuse disease, inflammation by high fat attenuation index (FAI)

  2. Change in total plaque volume (adjusted by vessel volume) and plaque composition detected by follow up CCTA [up to 5 years after index procedure]

    Change in total plaque volume (adjusted by vessel volume) and plaque composition detected by follow up CCTA

  3. Change in WSS detected by follow up CCTA [up to 5 years after index procedure]

    Change in hemodynamic parameter of wall shear stress (WSS) detected by follow up CCTA

  4. Change in APS detected by follow up CCTA [up to 5 years after index procedure]

    Change in hemodynamic parameter of axial plaque stress (APS) detected by follow up CCTA

  5. Change in SSI detected by follow up CCTA [up to 5 years after index procedure]

    Change in stenosis susceptibility index (SSI) detected by follow up CCTA

  6. Change in hemodynamic parameters delta fractional flow reserve detected by follow up CCTA [up to 5 years after index procedure]

    Change in hemodynamic parameters delta fractional flow reserve detected by follow up CCTA

  7. Change in physiological pattern by PPG derived by follow up CCTA [up to 5 years after index procedure]

    Change in physiological pattern by pullback pressure gradient (PPG) derived by follow up CCTA

  8. Change in dCT-FFR/ds detected by follow up CCTA [up to 5 years after index procedure]

    Change in dCT-FFR/ds detected by follow up CCTA

  9. Change in CT-FFR [up to 5 years after index procedure]

    Change in fractional flow reserve by CCTA

  10. Change in peri-coronary adipose tissue assessed by follow up CCTA [up to 5 years after index procedure]

    Change in peri-coronary adipose tissue assessed by follow up CCTA

  11. CCTA-derived features associated with precursors of ACS or CCS [up to 5 years after index procedure]

    CCTA-derived features associated with precursors of ACS or CCS

  12. Adverse cardiovascular event according to stenosis and plaque features, disease patterns, hemodynamic parameters, and fat metrics on CCTA along with physiologic assessment [up to 5 years after index procedure]

    A composite of cardiac death, vessel-related myocardial infarction (MI), or vessel-related ischemia-driven revascularization.

  13. Adverse cardiovascular event according to different treatment strategies according to stenosis and plaque features, fat metrics on CCTA along with physiologic assessments. [up to 5 years after index procedure]

    A composite of cardiac death, vessel-related myocardial infarction (MI), or vessel-related ischemia-driven revascularization.

Secondary Outcome Measures

  1. Anginal status [up to 5 years after index procedure]

    Change in Health Related Quality of Life (HRQL)

  2. Number of anti-anginal medication prescribed [up to 5 years after index procedure]

    Number of anti-anginal medication prescribed

  3. Clinical predictors of events [up to 5 years after index procedure]

    To find out the models with baseline characteristics including age, sex, cardiovascular risk factors and so on with the highest area under curve to predict a composite of cardiac death, vessel-related myocardial infarction (MI), or vessel-related ischemia-driven revascularization.

  4. Prognostic value of CCTA defined anatomy and plaque characterization [up to 5 years after index procedure]

    Prognostic value of CCTA defined anatomy including diameter stenosis, area stenosis and plaque characterization including plaque components, physiological on blood flow, diffuseness and inflammation.

  5. Prognostic value of WSS [up to 5 years after index procedure]

    Prognostic value of WSS

  6. Prognostic value of APS [up to 5 years after index procedure]

    Prognostic value of APS

  7. Prognostic value of SSI [up to 5 years after index procedure]

    Prognostic value of SSI

  8. Prognostic value of delta CT-FFR [up to 5 years after index procedure]

    Prognostic value of delta CT-FFR

  9. Prognostic value of pull pressure gradient [up to 5 years after index procedure]

    Prognostic value of pull pressure gradient

  10. Prognostic value of dCT-FFR/ds [up to 5 years after index procedure]

    Prognostic value of dCT-FFR/ds

  11. Prognostic value of per-coronary adipose tissue [up to 5 years after index procedure]

    Prognostic value of per-coronary adipose tissue derived fat attenuation index and other radiomics features.

  12. Prognostic value of integrated CCTA based lesion anatomy, plaque characterization, hemodynamic parameters, physiological patterns and per-coronary adipose tissue for ACS [up to 5 years after index procedure]

    Comparison of outcome discrimination ability.

  13. Prognostic value of integrated CCTA based lesion anatomy, plaque characterization, hemodynamic parameters, physiological patterns and per-coronary adipose tissue for cardiovascular events [up to 5 years after index procedure]

    Comparison of outcome discrimination ability.

  14. Relationship among CT-derived plaque qualification and quantification, and CT-defined pericoronary and epicardial fat metrics with physiological assessments. [up to 5 years after index procedure]

    Association among CCTA parameters (including diameter stenosis, area stenosis, plaque components) and physiologic indices (CT-FFR, PPG, delta-FFR, dCT-FFR/ds).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Inclusion Criteria:
  • Patients with an indication for CCTA.

  • Qualified patients who have signed a written informed consent form.

Exclusion Criteria:
  • Left ventricular ejection fraction < 35%

  • Acute ST-elevation myocardial infarction within 72 hours or previous coronary artery bypass graft surgery

  • Abnormal epicardial coronary flow (TIMI flow < 3)

  • Planned coronary artery bypass graft surgery after diagnostic angiography

  • Poor quality of CCTA or other reasons by core lab that are unsuitable for plaque, physiological or fat analysis

  • Patients with a stent in the target vessel

Contacts and Locations

Locations

Site City State Country Postal Code
1 Shanghai Zhongshan Hospital Shanghai China

Sponsors and Collaborators

  • Shanghai Zhongshan Hospital

Investigators

  • Study Chair: Junbo Ge, Professor, Fudan University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shanghai Zhongshan Hospital
ClinicalTrials.gov Identifier:
NCT05380622
Other Study ID Numbers:
  • CHART-20220510
First Posted:
May 19, 2022
Last Update Posted:
May 25, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 25, 2022